ASH 2020 | Administration of liso-cel for R/R LBCL in non-academic centers
Carlos Bachier, MD, Sarah Cannon Center for Blood Cancer, Nashville, TN, shares the findings of an investigation (NCT03744676) into non-university medical center-based administration of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) aggressive large B-cell lymphoma (LBCL). This Phase II OUTREACH study enrolled LBCL patients treated as inpatients or outpatients in non-university centers and found that treatment with toxicity monitoring was safe and effective in both cases. Promising response rates were seen for outpatients that were comparable to inpatients treated at university sites, and the incidence of cytokine release syndrome was low in both arms, with no ≥3 events. Recruitment for the trial is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Advisory boards: Novartis, CRISPR, BMS, Viracyte, Autolus, Nkarta
Speakers Bureau: Sanofi
